Cargando…
Metformin and Malignant Tumors: Not Over the Hill
Malignant tumors are a major cause of death, and their incidence is increasing worldwide. Although the survival rate for some cancers has improved, treatments for other malignant tumors are limited, and their mortality rate continues to increase. People with type 2 diabetes have a higher risk of mal...
Autores principales: | Leng, Weiling, Jiang, Juan, Chen, Bing, Wu, Qinan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8380287/ https://www.ncbi.nlm.nih.gov/pubmed/34429626 http://dx.doi.org/10.2147/DMSO.S326378 |
Ejemplares similares
-
Metformin and Malignant Tumors: Not Over the Hill [Response to Letter]
por: Leng, Weiling, et al.
Publicado: (2021) -
Metformin and Malignant Tumors: Not Over the Hill: A Short Comment [Letter]
por: Rastmanesh, Reza
Publicado: (2021) -
Effect of Metformin on Breast Density in Overweight/Obese Premenopausal Women
por: Leng, Weiling, et al.
Publicado: (2021) -
Evaluation of the Efficacy of the Hospital Glycemic Management System for Patients with Malignant Tumors and Hyperglycemia
por: Jiang, Juan, et al.
Publicado: (2021) -
The SGLT-2 Inhibitor Dapagliflozin Has a Therapeutic Effect on Atherosclerosis in Diabetic ApoE(−/−) Mice
por: Leng, Weiling, et al.
Publicado: (2016)